Efficacy of Tirzepatide for Weight Loss in China: Implications for the Global Obesity Epidemic

Frank Qian¹, Frank B Hu^{2

3

4}

Affiliations

¹ Section of Cardiovascular Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
² Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
³ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
⁴ Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Editorial

Frank Qian et al. JAMA. 2024.

. 2024 Aug 20;332(7):538-540.

doi: 10.1001/jama.2024.7928.

Frank Qian¹, Frank B Hu^{2

3

4}

¹ Section of Cardiovascular Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
² Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
³ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
⁴ Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

No abstract available

Comment on

Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
Zhao L, Cheng Z, Lu Y, Liu M, Chen H, Zhang M, Wang R, Yuan Y, Li X. Zhao L, et al. JAMA. 2024 Aug 20;332(7):551-560. doi: 10.1001/jama.2024.9217. JAMA. 2024. PMID: 38819983 Free PMC article. Clinical Trial.